R&D Spending Showdown: United Therapeutics Corporation vs Xencor, Inc.

Biotech R&D: United Therapeutics vs. Xencor's Decade of Innovation

__timestampUnited Therapeutics CorporationXencor, Inc.
Wednesday, January 1, 201424254900018516000
Thursday, January 1, 201524509800034140000
Friday, January 1, 201614760000051872000
Sunday, January 1, 201726460000071772000
Monday, January 1, 201835790000097501000
Tuesday, January 1, 20191182600000118590000
Wednesday, January 1, 2020357700000169802000
Friday, January 1, 2021540100000192507000
Saturday, January 1, 2022322900000199563000
Sunday, January 1, 2023408000000253598000
Loading chart...

Infusing magic into the data realm

The Evolution of R&D Spending in Biotech Giants

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and Xencor, Inc. have demonstrated contrasting trajectories in their R&D investments.

From 2014 to 2023, United Therapeutics Corporation has consistently outpaced Xencor, Inc. in R&D spending, with a peak in 2019 where their investment was nearly five times that of Xencor. However, Xencor has shown a steady increase, with their R&D expenses growing by over 1,200% from 2014 to 2023. This trend highlights Xencor's aggressive push towards innovation, despite being a smaller player.

As the biotech landscape evolves, these spending patterns offer a glimpse into the strategic priorities of these companies, with United Therapeutics focusing on maintaining its lead, while Xencor aims to close the gap.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025